Anterogen.Co.,Ltd.

KOSDAQ:A065660 Stock Report

Market Cap: ₩148.4b

Anterogen.Co.Ltd Past Earnings Performance

Past criteria checks 0/6

Anterogen.Co.Ltd's earnings have been declining at an average annual rate of -4.6%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 12% per year.

Key information

-4.6%

Earnings growth rate

-2.1%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate12.0%
Return on equity-2.0%
Net Margin-34.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?

Apr 04
Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?

Health Check: How Prudently Does Anterogen.Co.Ltd (KOSDAQ:065660) Use Debt?

Feb 05
Health Check: How Prudently Does Anterogen.Co.Ltd (KOSDAQ:065660) Use Debt?

Does Anterogen.Co.Ltd's (KOSDAQ:065660) Share Price Gain of 25% Match Its Business Performance?

Dec 14
Does Anterogen.Co.Ltd's (KOSDAQ:065660) Share Price Gain of 25% Match Its Business Performance?

Revenue & Expenses Breakdown

How Anterogen.Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A065660 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 246,659-2,3142,0934,147
31 Mar 246,490-3,4501,9865,258
31 Dec 236,500-2,8411,8085,384
30 Sep 236,288-3,2281,8115,763
30 Jun 236,233-3,7031,6405,598
31 Mar 236,467-4,1921,9304,561
31 Dec 226,591-6,8372,0324,658
30 Sep 227,538-6,4522,0204,488
30 Jun 227,793-5,3472,0934,352
31 Mar 228,304-3471,8754,300
31 Dec 218,122-5541,7934,194
30 Sep 216,585-1,3391,6104,209
30 Jun 215,873491,3843,928
31 Mar 214,732-6,2261,2924,154
31 Dec 204,151-4,3751,2694,007
30 Sep 204,177-6,7051,3213,949
30 Jun 204,169-8,1651,5483,690
31 Mar 204,065-4,1861,7442,994
31 Dec 194,148-4,0501,8302,533
30 Sep 193,9071,0931,4762,860
30 Jun 193,6613591,7102,425
31 Mar 193,560-1,5221,9581,936
31 Dec 183,607-9621,9221,870
30 Sep 183,765-3,0302,442787
30 Jun 184,328-1,4512,135787
31 Mar 184,446-4481,8031,225
31 Dec 175,3574471,7601,305
30 Sep 175,2841631,7821,398
30 Jun 175,066-1031,6941,740
31 Mar 174,757-1541,6191,715
31 Dec 164,8963721,5991,545
30 Sep 164,8138711,5161,061
30 Jun 165,0011,3481,400915
31 Mar 164,9861,3371,1061,152
31 Dec 153,532-581,294908
30 Sep 153,241-4911,3101,241
30 Jun 152,498-1,1351,2971,290
31 Mar 152,082-1,3011,531927
31 Dec 141,834-1,4161,2481,143
30 Sep 141,575-1,6818991,393
30 Jun 141,203-2,0801,2631,149
31 Mar 141,162-1,9031,0751,179
31 Dec 13916-1,8109701,059

Quality Earnings: A065660 is currently unprofitable.

Growing Profit Margin: A065660 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A065660 is unprofitable, and losses have increased over the past 5 years at a rate of 4.6% per year.

Accelerating Growth: Unable to compare A065660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A065660 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).


Return on Equity

High ROE: A065660 has a negative Return on Equity (-2.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies